𧬠Moderna $MRNA +4% premarket after FDA approves first-ever mRNA flu vaccine mFlusiva
The FDA just greenlit Moderna's mFlusiva -- the first mRNA-based flu vaccine -- for adults 50+, opening a huge new market for the company beyond COVID shots. This validates the mRNA platform at commercial scale and puts Moderna in direct competition with legacy flu vaccine makers. MRNA climbed 4% in premarket on the news. Not financial advice -- does this approval mark a real turning point for Moderna's post-COVID growth story?
β‘ 8 buzzing
162 views
π 0 subscribed
